Can analysts adopt a bullish outlook for OraSure Technologies, Inc. (NASDAQ:OSUR)?

May 26, 2018 - By Maria Brooks

Investors sentiment decreased to 0.83 in 2017 Q4. Its down 0.18, from 1.01 in 2017Q3. It dropped, as 45 investors sold OraSure Technologies, Inc. shares while 56 reduced holdings. 34 funds opened positions while 50 raised stakes. 53.79 million shares or 2.08% less from 54.93 million shares in 2017Q3 were reported.
Envestnet Asset Mngmt has invested 0% in OraSure Technologies, Inc. (NASDAQ:OSUR). Moreover, Globeflex Limited Partnership has 0.36% invested in OraSure Technologies, Inc. (NASDAQ:OSUR). Sei Invests Com holds 0% or 6,810 shares in its portfolio. 40,996 are held by Texas Permanent School Fund. Ameritas Prtnrs Inc has invested 0% of its portfolio in OraSure Technologies, Inc. (NASDAQ:OSUR). Tiaa Cref Management Limited Liability Corp holds 419,307 shares. Northern Tru Corp reported 0% stake. Moreover, Daruma Llc has 3.57% invested in OraSure Technologies, Inc. (NASDAQ:OSUR) for 3.04M shares. Rhumbline Advisers reported 0.01% of its portfolio in OraSure Technologies, Inc. (NASDAQ:OSUR). Plante Moran Financial Advisors Ltd Liability has 0% invested in OraSure Technologies, Inc. (NASDAQ:OSUR). 21,720 were accumulated by Alps Advisors. Comerica Commercial Bank reported 62,350 shares or 0.01% of all its holdings. Fiera Capital invested in 203,730 shares. Pub Employees Retirement System Of Ohio invested in 324,200 shares. Parametric Limited Com accumulated 132,781 shares or 0% of the stock.

Since February 15, 2018, it had 0 buys, and 2 selling transactions for $778,707 activity. On Thursday, February 15 the insider SMITH BRIAN sold $359,460.

OraSure Technologies, Inc. (NASDAQ:OSUR) Ratings Coverage

Among 3 analysts covering Orasure Technologies (NASDAQ:OSUR), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Orasure Technologies had 3 analyst reports since December 15, 2017 according to SRatingsIntel. The stock of OraSure Technologies, Inc. (NASDAQ:OSUR) has “Buy” rating given on Friday, February 2 by Canaccord Genuity. Jefferies maintained it with “Hold” rating and $17.5 target in Tuesday, February 13 report. Below is a list of OraSure Technologies, Inc. (NASDAQ:OSUR) latest ratings and price target changes.

13/02/2018 Broker: Jefferies Rating: Hold New Target: $17.5 Maintain
02/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $24.0 Maintain
15/12/2017 Broker: Raymond James Rating: Buy

The stock increased 0.81% or $0.13 during the last trading session, reaching $16.21. About 521,225 shares traded. OraSure Technologies, Inc. (NASDAQ:OSUR) has risen 34.91% since May 26, 2017 and is uptrending. It has outperformed by 23.36% the S&P500.

OraSure Technologies, Inc., together with its subsidiaries, develops, makes, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company has market cap of $989.84 million. It operates in two divisions, OSUR and DNAG. It has a 31.78 P/E ratio. The firm also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

More important recent OraSure Technologies, Inc. (NASDAQ:OSUR) news were published by: Globenewswire.com which released: “OraSure Announces 2018 First Quarter Financial Results” on May 02, 2018, also Streetinsider.com published article titled: “OraSure Technologies (OSUR) Announces Roberto Cuca as New CFO”, Globenewswire.com published: “OraSure Technologies Appoints New Chief Financial Officer” on May 04, 2018. More interesting news about OraSure Technologies, Inc. (NASDAQ:OSUR) was released by: Globenewswire.com and their article: “OraSure Technologies to Present at the UBS Global Healthcare Conference” with publication date: May 14, 2018.

OraSure Technologies, Inc. (NASDAQ:OSUR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: